JP7404331B2 - 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ - Google Patents

膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ Download PDF

Info

Publication number
JP7404331B2
JP7404331B2 JP2021500374A JP2021500374A JP7404331B2 JP 7404331 B2 JP7404331 B2 JP 7404331B2 JP 2021500374 A JP2021500374 A JP 2021500374A JP 2021500374 A JP2021500374 A JP 2021500374A JP 7404331 B2 JP7404331 B2 JP 7404331B2
Authority
JP
Japan
Prior art keywords
tregs
nucleic acid
mammalian
cells
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519107A5 (https=
JP2021519107A (ja
JPWO2019180724A5 (https=
Inventor
グロス、ギデオン
ウェインスタイン－マロム、ハダス
クローナー、アミット
Original Assignee
ガビッシュ－ガリラヤ バイオ アプリケーションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガビッシュ－ガリラヤ バイオ アプリケーションズ リミテッド filed Critical ガビッシュ－ガリラヤ バイオ アプリケーションズ リミテッド
Publication of JP2021519107A publication Critical patent/JP2021519107A/ja
Publication of JP2021519107A5 publication Critical patent/JP2021519107A5/ja
Publication of JPWO2019180724A5 publication Critical patent/JPWO2019180724A5/ja
Priority to JP2023210111A priority Critical patent/JP2024019533A/ja
Application granted granted Critical
Publication of JP7404331B2 publication Critical patent/JP7404331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
JP2021500374A 2018-03-23 2019-03-22 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ Active JP7404331B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023210111A JP2024019533A (ja) 2018-03-23 2023-12-13 膜結合型ＩＬ－１０を発現する遺伝子的にリプログラミングされたＴｒｅｇ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647084P 2018-03-23 2018-03-23
US62/647,084 2018-03-23
PCT/IL2019/050324 WO2019180724A1 (en) 2018-03-23 2019-03-22 Genetically reprogrammed tregs expressing membrane-bound il-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023210111A Division JP2024019533A (ja) 2018-03-23 2023-12-13 膜結合型ＩＬ－１０を発現する遺伝子的にリプログラミングされたＴｒｅｇ

Publications (4)

Publication Number Publication Date
JP2021519107A JP2021519107A (ja) 2021-08-10
JP2021519107A5 JP2021519107A5 (https=) 2022-03-31
JPWO2019180724A5 JPWO2019180724A5 (https=) 2022-03-31
JP7404331B2 true JP7404331B2 (ja) 2023-12-25

Family

ID=66448601

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500374A Active JP7404331B2 (ja) 2018-03-23 2019-03-22 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ
JP2023210111A Pending JP2024019533A (ja) 2018-03-23 2023-12-13 膜結合型ＩＬ－１０を発現する遺伝子的にリプログラミングされたＴｒｅｇ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023210111A Pending JP2024019533A (ja) 2018-03-23 2023-12-13 膜結合型ＩＬ－１０を発現する遺伝子的にリプログラミングされたＴｒｅｇ

Country Status (10)

Country Link
US (1) US20210347843A9 (https=)
EP (1) EP3768699B1 (https=)
JP (2) JP7404331B2 (https=)
KR (1) KR102943105B1 (https=)
CN (1) CN112088164A (https=)
AU (1) AU2019240370B2 (https=)
CA (1) CA3094927A1 (https=)
IL (1) IL277541A (https=)
SG (1) SG11202010454PA (https=)
WO (1) WO2019180724A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220186232A1 (en) * 2019-03-26 2022-06-16 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars
EP4536689A1 (en) * 2022-06-10 2025-04-16 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4289859A1 (en) * 2022-06-10 2023-12-13 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4565702A1 (en) * 2022-08-03 2025-06-11 Migal Galilee Research Institute Ltd. Chimeric membrane-bound cytokines incorporating costimulatory elements for enhancing anti-inflammatory function
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途
CN119331826B (zh) * 2024-12-18 2025-08-05 智在汉青生物科技(浙江)有限公司 用于增强细胞免疫疗法的表达非分泌型il-10的免疫细胞、制备方法及用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533542A (ja) 2000-05-24 2003-11-11 セル−サイ・コーポレーシヨン Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用
WO2003106616A2 (en) 2002-06-12 2003-12-24 Gavish-Galilee Bio Applications Ltd MEMBRANE-ANCHORED β2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
JP2008500014A (ja) 2003-10-14 2008-01-10 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ・フェルトレーテン・デュルヒ・デン・プレジデンテン 組換えワクチンおよびその使用
WO2010042654A2 (en) 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
US20130316404A1 (en) 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10
WO2017173410A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
US20170368144A1 (en) 2016-06-22 2017-12-28 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5275100A (en) * 1999-05-21 2000-12-12 Regents Of The University Of California, The Fluorescent protein indicators
US20050048587A1 (en) * 2003-07-17 2005-03-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
AU2013203561B2 (en) * 2009-05-15 2015-11-26 Irx Therapeutics, Inc. Vaccine immunotherapy
ES2612914T3 (es) * 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
MX2018007295A (es) * 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
CN107216395B (zh) * 2017-07-03 2018-07-20 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533542A (ja) 2000-05-24 2003-11-11 セル−サイ・コーポレーシヨン Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用
WO2003106616A2 (en) 2002-06-12 2003-12-24 Gavish-Galilee Bio Applications Ltd MEMBRANE-ANCHORED β2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
JP2008500014A (ja) 2003-10-14 2008-01-10 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ・フェルトレーテン・デュルヒ・デン・プレジデンテン 組換えワクチンおよびその使用
WO2010042654A2 (en) 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
US20130316404A1 (en) 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10
WO2017173410A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
US20170368144A1 (en) 2016-06-22 2017-12-28 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Andolfi G et al，Enforced IL-10 Expression Confers Type 1 Regulatory T Cell (Tr1) Phenotype and Function to Human CD4+ T Cells，Mol Ther，2012年，20・9，1778-1790
Blat D et al，Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells，Mol Ther，2014年，22・5，1018-1028
Jethwa H et al，Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?，Clin Immunol，2014年，150，51-63
Locafaro G et al，IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism，Mol Ther，2017年，25・10，2254-2269
Weinstein-Marom H et al，Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants，J Immunother，2016年，39・2，60-70

Also Published As

Publication number Publication date
EP3768699A1 (en) 2021-01-27
IL277541A (en) 2020-11-30
JP2024019533A (ja) 2024-02-09
WO2019180724A1 (en) 2019-09-26
US20210040169A1 (en) 2021-02-11
US20210347843A9 (en) 2021-11-11
JP2021519107A (ja) 2021-08-10
EP3768699B1 (en) 2025-11-12
AU2019240370B2 (en) 2024-03-07
SG11202010454PA (en) 2020-11-27
KR20210005602A (ko) 2021-01-14
AU2019240370A1 (en) 2020-11-19
CA3094927A1 (en) 2019-09-26
CN112088164A (zh) 2020-12-15
KR102943105B1 (ko) 2026-03-24

Similar Documents

Publication Publication Date Title
JP7404331B2 (ja) 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ
CN107074929B (zh) 嵌合自身抗体受体t细胞的组合物和方法
AU2021279184A1 (en) Polypeptide useful in adoptive cell therapy
KR20210003810A (ko) Treg 세포의 억제 특성을 향상시키기 위한 방법
JP7789666B2 (ja) Ｈｌａ特異的なキメラ抗原受容体
CN110857319B (zh) 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
US20230138428A1 (en) Chimeric receptors for use in engineered cells
Tal et al. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities
WO2019096115A1 (zh) 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
US20250144137A1 (en) Nucleic acid constructs for expressing polypeptides in cells
CN112423793A (zh) 肌肉特异性激酶嵌合自身抗体受体细胞的组合物和方法
CN114127287A (zh) 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
EP2267118A1 (en) Method for production of transfected cell
CN118434761A (zh) 组成型细胞因子受体
CA3141210A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
EP4467155A1 (en) Car-thytreg cells, compositions and uses thereof in immunotherapy
RU2774895C2 (ru) Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al
HK40042137A (en) Genetically reprogrammed tregs expressing membrane-bound il-10
US20240052015A1 (en) Inducible signalling protein
HK40063360A (en) Compositions and methods of chimeric autoantibody receptor t cells
CN121586727A (zh) 组成型细胞因子受体
JP2025515116A (ja) 制御性ｔ細胞の抑制活性を維持するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231213

R150 Certificate of patent or registration of utility model

Ref document number: 7404331

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150